Ziltivekimab
Based on 1 Customer Validation
Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease.
For research use only. We do not sell to patients.
- Purity: 99.75%
- CAS No.: 2226654-05-1
- Molecular Weight:145.39 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
|
IL-6 |
Ziltivekimab significantly reduces inflammatory biomarkers in chronic kidney disease patients with systemic inflammation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2226654-05-1
-
Appearance Liquid
-
Molecular Weight 145.39 kDa
-
Color Colorless to light yellow
-
SMILES
[Ziltivekimab]
-
Synonyms
COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (256 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021 Sep 28;117(11):e138-e140. [Content Brief]
[2]. Pergola PE, et al. Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE). J Am Soc Nephrol. 2024;35(1):74-84. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- Ziltivekimab
- 2226654-05-1
- COR-001
- MEDI-5117
- NN-6018
- WBP-216
- COR001
- COR 001
- MEDI5117
- MEDI 5117
- MEDI-5117
- NN6018
- NN 6018
- NN-6018
- WBP216
- WBP 216
- WBP-216
- Interleukin Related
- LDLR
- high-sensitivity C-reactive protein
- chronic kidney disease
- atherothrombotic disease
- secretory phospholipase A2
- systemic inflammation
- lipoprotein(a)
- fibrinogen
- haptoglobin
- serum amyloid A
- IL-6 ligand
- Inhibitor
- inhibitor
- inhibit